NCT04144855View on ClinicalTrials.gov

A Study to Evaluate the Tolerance and Pharmacokinetics of TQB3474 Injection

PHASE1UnknownINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

November 27, 2018

Primary Completion Date

November 27, 2020

Study Completion Date

May 30, 2021

Conditions
Advanced Solid Tumor
Interventions
DRUG

TQB3474 injection

This is a kind of heat shock protein (HSP90) inhibitor.

Trial Locations (3)

400000

NOT_YET_RECRUITING

Chongqing Cancer Hospital, Chongqing

550008

NOT_YET_RECRUITING

Guizhou Cancer Hospital, Guiyang

610000

RECRUITING

Yongsheng, Chengdu

Sponsors
All Listed Sponsors
lead

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

INDUSTRY